Design Therapeutics(DSGN)2024-11-07 21:06Financial Performance - Research and development (R&D) expenses for Q3 2024 were 13.3 million in Q3 2023, reflecting a decrease of approximately 10.3%[5] - General and administrative (G&A) expenses for Q3 2024 were 5.6 million in Q3 2023, a reduction of about 20.3%[5] - The net loss for Q3 2024 was 15.8 million in Q3 2023, indicating an improvement of approximately 17.5%[5] - The total operating expenses for Q3 2024 were 18.8 million in Q3 2023, a decrease of approximately 13.8%[10] Cash Position - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $254.1 million, expected to fund operations into 2029[6] Clinical Development - The company is on track to initiate the Phase 1 trial for Friedreich Ataxia (FA) in healthy volunteers in the first half of 2025, with patient dosing anticipated later in 2025[2] - Phase 1 development for Fuchs Endothelial Corneal Dystrophy (FECD) has been initiated, with initial data expected in the first half of 2025[3] - The company is advancing preclinical programs for Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) in preparation for future IND submissions[4] - The company aims to have multiple clinical proof-of-concept data sets from its GeneTAC™ pipeline over the next few years[2] Share Information - The weighted-average shares of common stock outstanding for Q3 2024 were 56,620,731, compared to 55,988,691 in Q3 2023[10]